Data PROpel Lynparza To Potential Prostate Cancer Megablockbuster
Combo Of PARP Inhibitor And J&J's Zytiga Delays Progression In All-Comers
The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.
You may also be interested in...
The limitations of launching during the pandemic will make it difficult to capitalize on a short window between the approvals.
The Swiss major's oncology business performed well in the third quarter with Kisqali sales catching the eye despite the specific problems that the pandemic has brought for breast cancer patients.